CN102138911B - Divalproex sodium sustained release tablets and preparation method thereof - Google Patents
Divalproex sodium sustained release tablets and preparation method thereof Download PDFInfo
- Publication number
- CN102138911B CN102138911B CN2011100756373A CN201110075637A CN102138911B CN 102138911 B CN102138911 B CN 102138911B CN 2011100756373 A CN2011100756373 A CN 2011100756373A CN 201110075637 A CN201110075637 A CN 201110075637A CN 102138911 B CN102138911 B CN 102138911B
- Authority
- CN
- China
- Prior art keywords
- divalproex sodium
- preparation
- tablet
- release
- slow releasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 title claims abstract description 44
- 229940028937 divalproex sodium Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 33
- 239000007939 sustained release tablet Substances 0.000 title abstract description 11
- 239000000203 mixture Substances 0.000 claims description 24
- 239000011230 binding agent Substances 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000000314 lubricant Substances 0.000 abstract description 5
- 239000003085 diluting agent Substances 0.000 abstract description 3
- 238000013268 sustained release Methods 0.000 abstract description 2
- 239000012730 sustained-release form Substances 0.000 abstract description 2
- 230000000181 anti-adherent effect Effects 0.000 abstract 1
- 239000003911 antiadherent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000003340 retarding agent Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 40
- 239000003814 drug Substances 0.000 description 31
- 238000000034 method Methods 0.000 description 23
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 10
- 229920002125 Sokalan® Polymers 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229960001631 carbomer Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- -1 valproate ion Chemical class 0.000 description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229940082484 carbomer-934 Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940031663 carbomer-974p Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the field of medicinal preparations, and particularly relates to divalproex sodium sustained release tablets and a preparation method thereof. The sustained release table comprises divalproex sodium, a retarding agent, a diluent, a disintegrant, a binder, a pH regulating agent, a lubricant, an antiadherent and the like.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, specifically, relate to a kind of divalproex sodium slow releasing preparation and preparation method thereof, the invention also discloses its preparation technology's relevant parameter.
Technical background
Divalproex sodium is central nervous system's class medicine, claims two-(2-Propylpentanoic) hydrogen sodium again, is the ionic compound that is formed by a part valproic acid and a part sodium valproate.It is that molecular formula is: C
16H
31O
2Na.Molecular weight is 310.41, and structural formula is:
Divalproex sodium is crystallization of white fiber shape or powder, odorless, and it is little puckery to distinguish the flavor of; Slightly draw moist.These article are dissolved in ethanol, dissolve in the water part omitted, and are almost insoluble in ether.
Divalproex sodium is the antiepileptic by Abbot laboratory research and development listing the earliest, is the wide spectrum antiepileptic, mainly acts on the central nervous system.The pharmacological research of animal is found that these article all have anticonvulsant action to the experimental model (general and part property) of various epilepsies.The all kinds epilepsy that comes to light to the people with the sample article has inhibitory action, and its main mechanism of action maybe be relevant with the concentration that increases GABA.
Because the too fast blood drug level peak value that makes of divalproex sodium general formulation rate of releasing drug is higher, is prone to have side effects, and is especially common with gastrointestinal reaction; Because main medication crowd be the epileptic, patient often can not take medicine on time in fine oneself's control, thereby commonly situation such as in administration, usually occurs missing and make therapeutic effect decline or not obvious.Related prescription and preparation method thereof has effectively solved the problems referred to above among the present invention.
It is the divalproex sodium slow releasing tablet of composite slow release framework material that people such as bibliographical information Venkatramana M.Rao have studied with strange E100 of You Te and Mei Duo show K4M; Can improve divalproex sodium onset rapidly after the rate of release of low pH environment makes its administration; Reduced the inside and outside difference of slow releasing tablet release degree; Can only reach 8 hours but this looks around the skeleton slow-release time, sufferer still needs multiple dosing, epileptic to occur easily missing every day; There are two pieces to prepare relevant Chinese patent CN99814629 and CN200580005453.2 with the divalproex sodium slow releasing tablet; With one piece of U.S. Pat 2004/0037880; At 20-40%, the material that produces valproate ion accounts for 50～55% of gross weight like the consumption that all requires divalproex sodium slow releasing composition medium-high viscosity hydroxypropyl methylcellulose in patent 99814629 and 200580005453.2.The preparation technology of its use relates to wet granulation and dry granulation: dry granulation is because its productive rate lower (being usually less than 60%); Often occur that granule was all once bad, tablet weight variation is big, content difference is big, batch between problems such as release degree difference is big, generally not as prefered method; Divalproex sodium is not too responsive to external environment factors such as acid, humidity; Wet granulation is as the most frequently used method of granulating; Be used in very much the preparation of divalproex sodium slow releasing tablet; But be difficult to be dried and carry out further tabletting because its physicochemical properties variation can appear in sodium valproate and divalproex sodium after moisture absorption; The prescription that is adopted among the present invention is fit to wet granulation, and the problem of the divalproex sodium moisture absorption that method for preparing possibly occur in the aforementioned patent can not appear in the preparation technology who adopts simultaneously, has improved preparation technology's productive rate greatly.
Summary of the invention
The purpose of this invention is to provide a kind of divalproex sodium slow releasing preparation and preparation method thereof, improve the medication compliance, the situation of avoiding the epileptic to miss repeating taking medicine takes place, and reduces the toxic and side effects that medicine brings.
Another object of the present invention is to solve the excessive problem that is not easy to swallow of divalproex sodium oral slow-releasing preparation volume.
The present invention is the improvement of divalproex sodium ordinary preparation; Experiment shows that taking a divalproex sodium slow releasing preparation every day can guarantee that 24 hours interior concentrations of body are in effective treatment window in its human body; And can stablize control plasma drug level peak value; Reduce the side effect that medicine brings, improve bioavailability of medicament to guarantee curative effect.By in the Chinese Pharmacopoeia 2010 editions to the requirement of the preparation stability investigation that makes an experiment; Its release performance stable uniform; Choose three batches and carry out the measuring of release in vitro degree; Releases degree relative standard deviation is less than 3% between batch, tests in the body to show in release in vitro percent and the body and be absorbed with good linear relationship.
The technical scheme that the present invention adopts is:
A kind of divalproex sodium slow releasing preparation is characterized in that said preparation has certain sustained release performance, and its slow release principle is mainly matrix sustained release tablet.Adjuvant of being selected for use and method for preparing all are easy to get feasible, and the method favorable reproducibility, suitability for industrialized production.
For this reason, the present invention provides a kind of divalproex sodium sustained-release tablet composition, it is characterized in that, is made up of divalproex sodium, blocker, binding agent, diluent, disintegrating agent, lubricant, antiplastering aid, pH regulator agent.Preferred composition of the present invention, the mass percent of each component is:
In the preferred composition of the present invention, wherein blocker is two kinds of different compositions, is blocker 1 and blocker 2, and both are respectively at the mass percent in compositions:
Blocker 1 5%-35%
Blocker 2 3%-15%.
In the composition of the present invention, wherein said blocker 1 is selected one or several the mixture in ethyl cellulose, hypromellose, carboxymethyl cellulose, methylcellulose, hydroxypropyl cellulose, polyacrylic acid, stearic acid, palm wax, the chitosan for use.Preferred hydroxypropyl methylcellulose, wherein the substitution value to its methyl and hydroxypropyl has requirement, and the methyl substituted ratio is at 15%-25%, and hydroxypropyl replaces ratio at 5%-15%, and its solution viscosity of 2% should be greater than 10000 centipoises.
Said blocker 2 is selected hydroxypropyl methylcellulose, hydroxypropyl cellulose, pregelatinized Starch, cellulose acetate, ethyl cellulose, polyglutamic acid, carbomer for use.Preferred carbomer, and select other oral type carbomer of high-purity-grade for use, like carbomer 934 P, carbomer 974P.
Said diluent is selected from the mixture of selecting one or more in the following adjuvant: lactose, starch, microcrystalline Cellulose, pregelatinized Starch, mannitol, chitosan, dextrin, preferable absorbent are pregelatinized Starch.
Selected binding agent is selected from mixture, the starch slurry of the second alcohol and water of polyvidone, water, dehydrated alcohol, different proportion, the aqueous dispersion of a certain proportion of hypromellose; Preferred alcohol solution, concentration is at 80%-99%.
Said lubricant is selected one or more the mixture in magnesium stearate, Pulvis Talci, hydrogenated vegetable oil, the stearyl alcohol, preferably talc powder for use.
Said antiplastering aid is selected Pulvis Talci, micropowder silica gel, stearyl alcohol, magnesium stearate for use, preferred micropowder silica gel, preferred micropowder silica gel.
Tricalcium phosphate, calcium hydrogen phosphate, dalcium biphosphate, dibastic sodium phosphate, sodium dihydrogen phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, sodium bicarbonate or similar phosphate, carbonate are selected in said pH regulator agent for use.
The special preferred compositions of the present invention is characterized in that, the quality of each component is: process 1000 divalproex sodium sustained-release tablet recipes
The most preferred compositions of the present invention is characterized in that, the quality of each component is: process 1000 divalproex sodium sustained-release tablet recipes
It is to obtain through screening that the present invention preferably fills a prescription, and screening process is following:
The present invention is gone on the market in the U.S. with the An Bote laboratory
The ER product is as reference preparation, through carrying out the drug release determination experiment, with similar factors F
2Be evaluation index, through orthogonal design and center-response surface method optimization prescription design, with the software match equation of each influence factor (hydroxypropyl methylcellulose consumption, pregelatinized Starch consumption, carbomer consumption etc.) and response value release degree similar factors (F2).Filter out multiple adjuvant and consumption proportion thereof, comprising: filleies such as starch, microcrystalline Cellulose, lactose, calcium hydrogen phosphate, tricalcium phosphate, pregelatinized Starch; Binding agents such as 30 POVIDONE K 30 BP/USP 30,5% low viscosity hydroxypropyl methylcellulose solution, dehydrated alcohol, 60～95% ethanol; Blocker such as hydroxypropyl methylcellulose, ethyl cellulose, carbomer 934 P; Fluidizer such as micropowder silica gel, Pulvis Talci, magnesium stearate.
The present invention finds about the experimental result (mainly being hardness, friability, release degree index) of filler; Starch and pregelatinized Starch are slower than lactose and microcrystalline Cellulose to the disintegration rate later stage of divalproex sodium slow releasing tablet; But tablet hardness and slice power are lower than microcrystalline Cellulose and lactose, are unfavorable for the requirement of tablet coating, transportation, storage.
The present invention finds about the experimental result of wetting agent; Polyvidone, 60% ethanol/water solution, 5% low viscosity hydroxypropyl methylcellulose are used for its granulation and will be prone to cause the powder body moistening inhomogeneous; Be difficult to granulate or the particle size distribution that makes is wide, be not suitable for amplifying and produce tabletting (potential risk that has tablet weight variation to exceed standard); The 80%-90% ethanol that optimizes can well make and form particle between powder, the particle size distribution that productive rate higher (being higher than 70%) makes narrow (leading indicator is investigated D50), suitable tabletting.
The present invention finds about the experimental result of blocker; Ethyl cellulose is the most obvious to the slow controlled-release effect of divalproex sodium; But exist the release terminal point too late, or the release degree does not reach more than 80% in the scheduled time, has the part medicine to be wrapped in the ethyl cellulose cellulosic material; Use separately hydroxypropyl methylcellulose as slow controlled-release material, the normal existence prominently released equivalent risk, and processes the divalproex sodium slow releasing tablet with it separately and have the pH dependency, and low pH drug release is slow, and the pH back that raises discharges and quickens, and the inside and outside dependency is poor; There are two kinds of models of 934P and 974P to be suitable for slow releasing tablet in the carbomer series; Because wetting agent such as unsuitable too by force water of full-bodied hydroxypropyl methylcellulose viscosity in wet-granulation process commonly used or 15% 30 POVIDONE K 30 BP/USP, 30 solution are granulated; And carbomer is fit to wet granulation and also is amplified in the suitability for industrialized production easily by the ethanol moistening of 60-95% and the suitable viscosity of generation.The present invention filters out 934P and hydroxypropyl methylcellulose pluralgel matrix sustained release tablet according to the slow-release time demand; Be aided with pH dependency and the prominent risk of releasing that the agent of microenvironment pH regulator has reduced slow releasing tablet of the present invention; Make the disintegrate under intestinal environment of its skeleton more complete; Discharge terminal point than hydroxypropyl methylcellulose matrix sustained release tablet more near 100%; Improved the interior dependency of release degree,, adopted Central Composite-Response Surface Method to optimize the amount ranges that an optimized prescription through using data statistics software; Used the prescription of minimum gross weight in adopting in the optimization range, and can obtain than commonsense method adjuvant still less, the slow releasing tablet of small size more makes preferably the swallowing of divalproex sodium sheet of heavy dose of specification.
The present invention comprises that also preparation of compositions method of the present invention comprises the steps:
Granule intermediate preparation: get the medicine and the adjuvant of recipe quantity, mix, add binding agent, adopt fluidized bed granulation method or wave the granulation of granulator granulation.With prepared particle drying, behind the certain hour, granule is sieved; Choose the suitable granule of size, measure its moisture, the qualified back of moisture adds the lubricant of recipe quantity; Mix homogeneously is inserted tablet machine, and debugging pressure makes it in optimum range; Tabletting is got the recipe quantity coating material and is mixed with coating solution, with coating solution atomizing carrying out coating.Coating finishes the after drying certain hour, and the divalproex sodium slow releasing tablet gets product.
This method also comprises: direct compression process: get the medicine and the adjuvant of recipe quantity, respectively it is crushed to certain grain size, behind 80 to 120 eye mesh screens, mix homogeneously is inserted in the tablet machine tabletting.
The present invention selects the prescription of optimization for use; Adopt fluidized bed granulation method, wave one or more method of granulating in granulator granulation or the wet granulator granulation; Adopt pressed disc method to prepare the divalproex sodium slow releasing tablet then, also can adopt direct compressing dry granulation to prepare slow releasing tablet.
The present invention is owing to use multiple blocker to form the pluralgel skeleton, and blocker 2 can significantly reduce the consumption of blocker 1; Compound blocker has better inside and outside dependency than single blocker, meets slow-release material release behavior is more discharged near zero level.The present invention has reduced pH and has changed the influence to divalproex sodium release degree, thereby reduced the inside and outside difference of drug release behavior owing to used the pH regulator agent.The slow release principle of slow releasing tablet of the present invention belongs to framework controlled release, and this type slow releasing tablet stability is superior to the coating type slow releasing tablet, is difficult for causing because of the variation of outer coating that the prominent of medicine release.Thin film coating material can improve the stability of slow releasing tablet simultaneously, and it is stable to ensure drug quality, and above-mentioned thin film coating material can be selected one or more in Opadry system type thin film coating material, the low viscosity hydroxypropyl methylcellulose for use.Because the adjuvant of employing optimization prescription ratio and principal agent are at the mixing and blending machine mix homogeneously; Adopt the top-jet-type fluid bed to spray into binding agent and can obtain suitable size particles, adopt oscillating granulator to prepare the granule intermediate again after also can joining binding agent in the powder body, select the suitable granule intermediate of particle diameter; With carry out tabletting after the mix lubricant; The tablet character can be selected circle, ellipse or capsule-type, and the tablet of preferred capsule-type is convenient to sufferer and is swallowed.
The invention has the advantages that:
(1) the present invention's divalproex sodium slow releasing tablet, the preparation process is simple, under laboratory scale, can accomplish the amplification production of 10000-30000 unit.
(2) slow releasing tablet of the present invention's preparation; The animal body giving drugs into nose is for dynamics research; With the ordinary preparation equivalence, do not produce the problem that reduces bioavailability because of slow releasing function, it discharges model and has reduced the plasma drug level peak value; Thereby reduced the possibility that toxic and side effects produces, taken the compliance that has once improved patient's medication every day.
(3) the present invention's slow releasing preparation is investigated through accelerated test, under 40 ℃, the condition of relative humidity 75% in 6 months stable, the medicament contg of character, related substance all in controlled range, suitability for industrialized production.
The study on the stability of table 1 batch 101105 divalproex sodium slow releasing tablet
The study on the stability of table 2 batch 101103 divalproex sodium slow releasing tablet
The study on the stability of table 3 batch 101101 divalproex sodium slow releasing tablet
The screening process of the different prescriptions of table 4 (it is heavy to investigate hardness, particle size distribution, slamp value, compressibility index and total sheet)
Table 1
Table 2
Table 3
Table 4
Description of drawings
The release in vitro degree of Fig. 1 optimizing prescriptions gained divalproex sodium slow releasing tablet
The screening of the compound framework material of Fig. 2
Fig. 3 is through the process of the main controlled slowly releasing adjuncts dosage optimization of software match
The specific embodiment
Below be the specific embodiment of the present invention, described embodiment is in order to further describe the present invention rather than restriction the present invention.All technical schemes with the present invention's equivalence all belong to protection scope of the present invention.
Embodiment 1
1000 divalproex sodium sustained-release tablet recipes
Preparation process and technology (waving the granulation machine granulation):
Get recipe quantity medicine, microcrystalline Cellulose, hydroxypropyl cellulose, carbomer, kindly reach, calcium hydrogen phosphate, subsequent use through in stirring mixer, mixing behind 80 eye mesh screens after 1 hour.It is an amount of to get 15% povidone solution, is injected to stir in the subsequent use powder to process soft material.Open and wave granulator, soft material through 24 eye mesh screens, is extruded the granule that forms suitable length; Be positioned in the baking oven 70 degrees centigrade of dryings 60 minutes; Carry out the inspection of the uniformity and water content, qualified after, add the magnesium stearate and the micropowder silica gel of recipe quantity; Mix joining tabletting in the tablet machine after 1 hour, both got the divalproex sodium slow releasing tablet.
Embodiment 2
1000 divalproex sodium sustained-release tablet recipes
8% low viscosity hydroxypropyl methylcellulose aqueous solution is an amount of
Preparation process and technology:
With medicine and the medicine, microcrystalline Cellulose, hydroxypropyl cellulose, carbomer of getting recipe quantity, kindly reach, calcium hydrogen phosphate pulverizes, and after in stirring mixer, mixing 1 hour behind 80 eye mesh screens, powder body placed the fluidized bed body.Dispose 8% low viscosity hydroxypropyl methylcellulose aqueous solution; Add the micropowder silica gel of recipe quantity and stir and make it into suspension; Adopt fluid bed to granulate, fluidized bed granulation technology is: the peristaltic pump transfusion speed is that 3ml/min, air compressor pressure are 35 ℃ of 2Bar, fluid bed EATs; Fluidisation is got 20-40 order size particles after a period of time, behind 70 degrees centigrade of dry 1h, carry out the inspection of the uniformity and water content, qualified after, add the Pulvis Talci of recipe quantity, mix in the mixer to join after 1 hour and carry out tabletting in the tablet machine, both slow releasing tablet.
Embodiment 3
1000 divalproex sodium sustained-release tablet recipes
Preparation technology:
The preparation technology of slow releasing tablet label:
With medicine and the medicine, microcrystalline Cellulose, hydroxypropyl cellulose, lactose, carbomer of getting recipe quantity, kindly reach, calcium hydrogen phosphate pulverizes; After in stirring mixer, mixing 1 hour behind 80 eye mesh screens; The magnesium stearate and the Pulvis Talci that add recipe quantity; Mix in the mixer to join after 0.5 hour and carry out direct compression in the tablet machine, both got slow releasing tablet.
Prescription
Preparation technology:
The preparation technology of slow releasing tablet label:
With medicine and the medicine, microcrystalline Cellulose, hydroxypropyl cellulose, carbomer of getting recipe quantity, kindly reach, calcium hydrogen phosphate pulverizes, after in stirring mixer, mixing 1 hour behind 80 eye mesh screens, this powder body is subsequent use.Dispose 15% an amount of povidone solution, as the micropowder silica gel that adds recipe quantity in the solution and stir and make it into suspension, join and process soft material in the medicament powder.Open and wave granulator, soft material is put into through sieve aperture, sieve aperture is selected the 16-20 eye mesh screen; Form the granule of moderate length, be positioned in the baking oven 40 degrees centigrade of dryings 45 minutes, carry out the inspections of the uniformity and water content; After qualified; The Pulvis Talci that adds recipe quantity mixes in the mixer to join after 1 hour and carries out tabletting in the tablet machine, has both got slow releasing tablet.
Claims (1)
1. a divalproex sodium slow releasing tablet is characterized in that, the content of each composition is following in the slow releasing tablet:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100756373A CN102138911B (en) | 2011-03-28 | 2011-03-28 | Divalproex sodium sustained release tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100756373A CN102138911B (en) | 2011-03-28 | 2011-03-28 | Divalproex sodium sustained release tablets and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102138911A CN102138911A (en) | 2011-08-03 |
| CN102138911B true CN102138911B (en) | 2012-12-12 |
Family
ID=44406856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100756373A Active CN102138911B (en) | 2011-03-28 | 2011-03-28 | Divalproex sodium sustained release tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102138911B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230380B (en) * | 2013-05-06 | 2015-02-18 | 北京四环制药有限公司 | Divalproex sodium enteric-coated tablet core as well as preparation method and application thereof |
| CN104146976B (en) * | 2014-08-06 | 2017-02-15 | 沈阳药科大学 | Heavy-load valproic acid drug sustained release tablet and preparation method thereof |
| CN106389368B (en) * | 2015-07-29 | 2021-11-12 | 四川科瑞德制药股份有限公司 | Sodium valproate sustained-release preparation and preparation process and application thereof |
| CN107028907B (en) * | 2016-02-04 | 2021-05-14 | 成都康弘药业集团股份有限公司 | Divalproex sodium sustained-release tablet |
| CN107811985B (en) * | 2016-09-13 | 2021-05-28 | 四川科瑞德制药股份有限公司 | Anti-epileptic sustained-release preparation and preparation method and application thereof |
| CN109674758A (en) * | 2019-02-25 | 2019-04-26 | 湖南博隽生物医药有限公司 | A kind of Divalproex sodium sustained-release tablet and preparation method thereof for treating epilepsy |
| CN113304117B (en) * | 2021-04-30 | 2023-05-12 | 山东京卫制药有限公司 | Preparation method of sodium valproate sustained release tablet |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335769A (en) * | 1998-12-18 | 2002-02-13 | 艾博特公司 | Controlled release formulation of divalproex sodium |
| CN1921838A (en) * | 2004-02-19 | 2007-02-28 | 兰贝克赛实验室有限公司 | Extended release pharmaceutical compositions of divalproex sodium |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003240164A1 (en) * | 2002-06-07 | 2003-12-22 | Ranbaxy Laboratories Limited | Extended release formulation of divalproex sodium |
-
2011
- 2011-03-28 CN CN2011100756373A patent/CN102138911B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335769A (en) * | 1998-12-18 | 2002-02-13 | 艾博特公司 | Controlled release formulation of divalproex sodium |
| CN1921838A (en) * | 2004-02-19 | 2007-02-28 | 兰贝克赛实验室有限公司 | Extended release pharmaceutical compositions of divalproex sodium |
Non-Patent Citations (1)
| Title |
|---|
| YIHONG QIU et al.Once-a-Day Controlled-Release Dosage Form of Divalproex Sodium I: Formulation Design and In Vitro/In Vivo Investigations.《JOURNAL OF PHARMACEUTICAL SCIENCES》.2003,第92卷(第6期),1167页"实验"部分至1172页"结果及讨论"部分. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102138911A (en) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102138911B (en) | Divalproex sodium sustained release tablets and preparation method thereof | |
| EP2777696B1 (en) | Preparation of stable pharmaceutical dosage forms | |
| CN102579381B (en) | Guanidine hydrochloride sustained release preparation and preparation method thereof | |
| CN102091051B (en) | Allopurinol dual-release preparation and preparation method thereof | |
| CN101851247B (en) | Composition containing clopidogrel bisulfate crystal particles | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN101810628B (en) | Melbine glipizide tablet and preparation method thereof | |
| CN105434386B (en) | A kind of sustained-release tablet containing highly-water-soluble active constituent and preparation method thereof | |
| CN102755301B (en) | Glimepiride tablet and preparation method thereof | |
| CN103263395A (en) | Telmisartan tablet preparation and preparation method thereof | |
| CN104546732A (en) | Dexibuprofen sustained-release tablet and preparation process thereof | |
| CN102764254B (en) | A kind of levetiracetam medicinal composition and preparation method thereof | |
| WO2013189305A1 (en) | Valsartan-amlodipine compound solid preparation and preparation method therefor | |
| CN101342177B (en) | Lornoxicam double-layer sustained release tablets | |
| JP2006176496A (en) | Solid agent and process for producing the same | |
| CN102846573A (en) | Silibinin double-layer slow-release tablets and preparation method thereof | |
| CN109700773B (en) | Ticagrelor preparation composition and preparation method thereof | |
| CN111617048B (en) | Erlotinib sustained release preparation for treating non-small cell lung cancer | |
| CN103655504B (en) | Dexketoprofen trometamol quick-release and slow-release double-layer tablet and preparation technology thereof | |
| CN101940560A (en) | Minocycline hydrochloride sustained-release tablets and method for preparing same with different specifications | |
| CN103371981A (en) | Compound repaglinide-metformin hydrochloride solid quick-release preparation and preparation method and application thereof | |
| RU2441651C1 (en) | Method for production of clozapine pharmaceutical composition in form of tablets and pharmaceutical composition | |
| CN106727375B (en) | Agomelatine tablet and preparation method thereof | |
| CN111249246A (en) | Levetiracetam sustained-release tablet and preparation method thereof | |
| CN101244068B (en) | Hemsleyadin sustained-release preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHONGSHUAI PHARMACEUTICAL SCIENCE AND TECHNOLOGY I Free format text: FORMER OWNER: SUN WEIDONG Effective date: 20140123 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140123 Address after: 18, A1, 7, Holly Street, 450001 hi tech Zone, Henan, Zhengzhou Patentee after: ZHONGSHUAI PHARMACEUTICAL SCI & TECH INCORPORATED CO., LTD. Address before: 18, building 7, building A, bio Pharmaceutical Industrial Park, 450001 Holly Road, Gaoxin District, Henan, Zhengzhou Patentee before: Sun Weidong |